Oncology/Hematology
<ѻý class="page-description">News, opinions and meeting coverage in oncology/hematology.— Complete responses in 21% of patients treated with single-agent revumenib
Latest in Oncology/Hematology
Patients with complete response can have long treatment-free interval, study suggests
More than 40% of adults, half of children met response criteria, majority of responses durable
News, features, and commentary about cancer-related issues
Results "signal a paradigm shift," expert says
News, features, and commentary about cancer-related issues
Results "signal a paradigm shift," expert says
Oncology/Hematology Case Studies
Rare condition can be deadly without early diagnosis and treatment
Nonspecific presentation impedes early diagnosis of rare indolent tumor in older man
Be aware of the potential for secondary malignancy in relation to LCH diagnosis, researchers urge
More in Oncology/Hematology
Greatest diagnostic accuracy with experienced dermatologists using dermoscopy
Health news and commentary gathered by ѻý staff
But absence of significant OS benefit raises questions about long-term benefit, expert says
Other IKCS news: closer look at belzutifan safety, challenges of triplet therapies for RCC
Improvements seen in pain, neuropathy, and cognitive function
Possible guidance for use of adjuvant immunotherapy in high-risk, non-metastatic disease
Delegates express concerns that PPE doesn't always cover women, who are more at risk of exposure
Better OS, PFS, response rate, but newer combination strategies not included
USPSTF screening recommendations, broader indication for ribociclib, OS win for pembrolizumab
VA analysis finds men with limited life expectancy still getting aggressive treatment
More IKCS news: Long-term survival benefit with nivolumab/ipilimumab, disease-slowing surgery
Health news and commentary gathered by ѻý staff
Low rate of recurrence with surgery or nonsurgical options, but data can inform decisions
Confirmed responses in one-fourth to one-third of patients with refractory disease
